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.82 ± 0.80 ng/mL, P = 0.687) and BMD of lumbar spines (0.55 ± 0.01 vs. 0.57 ± 0.01 g/cm^2, P = 0.159) and left hip (0.56 ± 0.01 vs. 0.56 ± 0.01 g/cm^2, P = 0.926).
Conclusions:
Children of HBV mothers with and without TDF treatment during late pregnancy had comparable long-term growth, renal function, and bone development up to 6-7 years after delivery.
Introduction
Hepatitis B virus (HBV) infection is a global health problem and mother-to-infant transmission is the major source of chronic HBV infection in endemic areas. (1) Immunoprophylaxis with hepatitis B immunoglobulin (HBIG) and vaccine starting soon after birth achieves >90% of efficacy in preventing maternal transmission of HBV. (2, 3) However, approximately 5-10% of infants born to highly viremic mothers are still infected despite immunoprophylaxis. (4) (5) (6) Recently, many studies have demonstrated that oral antiviral nucleos(t)ide analogues use in highly viremic mothers during late pregnancy successfully decreases maternal viral load and thus prevents mother-to-infant transmission. (7) The nucleos(t)ide analogues used during pregnancy include lamivudine, telbivudine, and tenofovir disoproxil fumarate (TDF). Among these nucleos(t)ide analogues, professional organization guidelines recommend TDF as a preferred choice, owing to its antiviral potency, safety data and lower rate of resistance. (8, 9) Although TDF is generally well tolerated, decreases in bone mineral density (BMD) and renal function impairment can occur in adult patients with long-term use. (10, 11) Given the increasing use of TDF in highly viremic HBV-infected pregnant women, data on the effects of fetal TDF exposure on children's growth, renal function, and bone development are urgently needed. Data from human immunodeficiency virus (HIV) literature are available but have been limited and controversial with most studies suggesting no effect of fetal TDF exposure on fetal/infant growth and/or bone development, and some studies showing decreased linear growth or bone mineral content in infants. (12, 13) Current studies involving HBV-infected women and their infants reported only short-term outcomes no longer than one year after birth. (14) (15) (16) (17) Long-term safety data for children is anticipated but is insufficient. (9) In this study, we reported the renal function, long-term growth parameters, as well as bone development assessed by BMD measurements and serum markers related to bone metabolism, of the children born to HBV-infected mothers with and without TDF treatment from [30] [31] [32] gestational weeks until 1 month postpartum in a prospective, multisite trial.
Subjects and Methods

Subjects
Children whose mother participated in a clinical trial (ClinicalTrials.gov identifier, NCT 01312012) on TDF use during late pregnancy to interrupt mother-to-infant transmission of HBV were invited to join the present study. The trial was a prospective, multisite, open-labeled, non-randomized controlled trial and we continue to enroll eligible HBV-infected pregnant women and their infants. (15) Participating mothers were HBV-infected pregnant women 20-40 years of age with an HBV DNA level ≥ 7.5 log10 IU/mL (=8.0 log10 copies/mL) and they joined in the control or TDF group based on their willingness. Mothers who had used antiviral treatment during the first and/or second trimester were excluded. Mothers with major systemic diseases, including renal insufficiency, heart disease, malignancy, liver cirrhosis, abnormal alanine aminotransferase (ALT) level over five times the upper limit of normal (40 U/L), or hepatic decompensation, co-infected with HIV or hepatitis C virus, or with evidence of fetal congenital anomaly were excluded.
From April 2011 to July 2016, mothers in the TDF group received TDF 300 mg once daily from gestational week 30-32 until 1 month following delivery, which was compatible with recommendations at that time. (18) Mothers in the control group did not receive antiviral therapy. All infants received HBIG 0.5 mL (100 IU) within 24 hours of birth and hepatitis B vaccine at 0, 1, and 6 months. Mothers in the TDF group 9 were advised not to breast-feed during the first month because safety data regarding neonatal exposure to TDF through breast milk was insufficient in 2011-2016 (18) .
Breast-feeding was encouraged after discontinuing TDF treatment. All the participating children were followed up at 0, 6 and 12 months of age. (15) These children were invited to join the present long-term follow-up study after 2 years of age and were followed once a year according to their willingness during the period from November 2015 to August 2018. A total of 212 children candidates, including 119 in the TDF group and 93 in the control group, were invited. The study was approved by the Institutional Review Board and informed consent was obtained from these children and children's parents or guardians.
Methods
At each visit, children's weight and height were measured. Age and sex-adjusted z-scores of body weight and height were calculated based on the WHO International Child Growth Standards. (19) Serum ALT, creatinine, calcium, phosphorus, bone specific alkaline phosphatase (BSAP) (LIAISON BAP OSTASE assay, DiaSorin, Italy), 25(OH)-vitamin D (calcidiol) (Elecsys Vitamin D Total assay, Roche) levels and HBV serological markers, including hepatitis B surface antigen (HBsAg) and its antibody (anti-HBs), were tested. Estimated glomerular filtration function (eGFR) was calculated by Schwartz formula. (20) According to parents' and children's willingness, dual-energy x-ray absorptiometery (DXA) scans (GE lunar Prodigy, Wisconsin, U.S.A.) of the lumbar spines (L1-4) and the left hip were performed to evaluate BMD.
All participating children received DXA scans at the same site, National Taiwan University Hospital. All DXA scans were conducted on the same machine by the same technologist team. Phantom test was routinely performed for daily quality control.
Statistical Analyses
Statistical analyses were performed using Stata software (version 11.2, Stata Corporation). Two-sided P ≤ 0.05 was considered statistically significant. Continuous variables were summarized as means with standard deviations or medians with interquartile ranges. The group differences were examined using the Mann-Whitney test for continuous variables or the chi-square test or Fisher's exact test for categorical variables. During childhood growth, many physiological processes may affect bone metabolism and related markers. The reference values of these markers vary among children with different age. (21) HBV infection may cause ALT elevation. Therefore, serum ALT, calcium, phosphorus, BSAP, calcidiol and BMD were compared between the TDF and control group with adjustment for age, sex, and HBV status by means of multiple linear regression. For the comparisons that were adjusted by covariates, data were reported as adjusted means with standard errors.
Results
One hundred and twenty-eight children, 71 in TDF and 57 in control group, completed 255 follow-up visits. Of the 128 children enrolled, one child (1/71, 1.4%) in the TDF group and six children (6/57, 10.5%) in the control group had chronic HBV infection. Each child joined one to three times of follow-up visits with an interval of 12 months between two visits. Table 1 lists the number of children and visits by group.
Children's age at each visit ranged from 2.0 to 7.0 (median, 4.08) years, and was comparable between the TDF and control group ( Table 2 ). The times of follow-up visits were comparable between the TDF and the control group (Table 1) .
Growth Indices
The z-scores for weight-for-age and z-scores for height-for-age were comparable between the TDF group and control group ( Table 2 ). Figure 1 depicts the medians and interquartile ranges of the z-scores, based on the WHO international child growth standards, in different age groups with comparison to these children's z-scores for weight and height at 12 months of age. (15) The rate of breast milk ingestion, including exclusive breastfeeding and mixed breast milk and formula feeding, was lower in the TDF vs. control group (43.7% vs.
66.7%, P = 0.009). In the TDF group, children with and without history of breast milk ingestion had comparable z-scores for weight-for-age and z-scores for height-for-age (Supplementary table) .
Markers related to Bone Development
Children in the TDF and control group had similar serum calcium, phosphorus, BSAP and calcidiol levels after adjustment for age, sex and HBV status by multiple linear regression (Table 2) .
Bone Mineral Density
A total of 73 children contributed 124 DXA scans, including 71 in the TDF group and 53 in the control group. The BMD of the lumbar spines (L1-L4) and the left hip were similar between the TDF and control group after adjustment for age, sex and HBV status by multiple linear regression (Table 3 ). Figure 2 depicts the relationship of BMD and age by group. Both the BMD of the lumbar spines and the left hip increased with age. Children in the TDF and control group had comparable BMD levels.
Renal Function
Children in the TDF group had similar eGFR, calculated by Schwartz formula, (20) with those in the control group (Table 2) .
Immunity against HBV
The anti-HBs levels and the percentages of children with adequate anti-HBs levels (≥ 10 mIU/mL) were comparable between the TDF and control group. Children with chronic HBV infection were not included in the analysis of anti-HBs (Table 4) .
No children who were HBsAg-negative at enrollment of the present study became HBsAg-positive during follow-up.
Discussion
This study presents the long-term outcomes of growth, bone development, renal function, and immunity against HBV in children born to highly viremic HBV-infected mothers with and without TDF treatment during late pregnancy until 1 month postpartum. Our results were collected prospectively and coupled with longitudinal assessment from birth. (15) Children with prenatal exposure to TDF had comparable growth, renal function, bone development and anti-HBs levels in un-infected children with those un-exposed to TDF. In addition to the short-term safety data from previous reports, (14) (15) (16) (17) our data provide evidences to support clinicians and patients to use TDF during late pregnancy and assure safety on children's long-term growth, renal function and bone development.
Previous studies showed that TDF passes placenta with a cord-to-maternal blood ratio ranged from 0.60 to 1.03 with chronic dosing in pregnant HIV-infected women. (12, 22) Tenofovir could be detected in the meconium of infants born to mothers taking TDF during pregnancy and the meconium tenofovir concentrations were not associated 13 with infant's weight and length within 30 days of birth. (23) Previous studies of TDF use during late pregnancy to prevent maternal transmission of HBV reported no effect on infant's growth at birth and at 6-12 months of age. (14) (15) (16) (17) Data on the long-term growth outcome in children with fetal exposure to TDF are limited, mainly from HIV-infected women and their children. In those HIV studies, TDF was not the only antiviral drug used but as part of combination antiviral therapy. By comparing the growth parameters in children born to HIV-infected, antiviral-treated women with and without a TDF-containing regimen, there was no evidence that in utero TDF exposure affected children's growth at 2-6 years of age. (24, 25) In our study, TDF was the only antiviral drug used and the prospective long-term follow-up data show that prenatal exposure of TDF in children born to HBV-infected mothers does not affect children's growth up to 6-7 years of age. The growth of the children in both TDF and control group is comparable to that of general population, as specified by the WHO international child growth standards, which describe normal child growth under optimal environmental conditions and can be applied to all children worldwide. (19) The safety of antiviral therapy during breastfeeding has not been well studied in HBV-infected women. In HIV-infected mothers treated with TDF, tenofovir in breast milk was detected with trivial concentrations. (26) Currently, professional organization guidelines generally allow breastfeeding during tenofovir therapy in HBV-infected mothers and suggest to discuss with mothers the low-level exposure to infants due to insufficient long-term safety data. (8) Our data provide evidence that children with and without neonatal exposure to TDF through breast milk had comparable long-term growth.
Long-term use of TDF is associated with BMD reduction in adult patients with HIV (27, 28) and HBV (10, 29) infection. In those studies, the treatment duration ranged 14 from 12 to 60 months. (10, (27) (28) (29) Few studies addressed the bone health of infants and children with in utero exposure to TDF, and the outcome measurements varied from hand/wrist/spine radiographs, (30) fetal femur and humerus length assessed by ultrasound, (31) bone metabolism markers, (32) to DXA scans. (13, 23) Of those studies, only one study of HIV-exposed but uninfected infants with maternal TDF treatment for more than 8 weeks in late pregnancy reported lower neonatal bone mineral content in TDF-exposed infants. (13) Other studies of infants born to HIV-infected mothers receiving TDF-containing antiviral therapy with treatment duration ranged from 3 to 41 gestational weeks reported no difference in fetal femur and humerus length z scores, (31) bone metabolism markers, including BSAP and C-terminal telopeptide of type I collagen, (32) and whole bone mineral content at 0-4 weeks of age. (23) Unlike the HIV-infected mothers who might use TDF throughout the entire pregnancy, and might receive multiple antiviral drugs in addition to TDF, (13, 23, 31, 32) HBV-infected pregnant women usually use TDF as monotherapy during late pregnancy to prevent maternal transmission. (14) (15) (16) (17) Longer treatment duration and possible confounding factors, such as use of other antiviral drugs, co-morbidities, and diverse study participants from different sites/countries may result in the difference in neonatal bone mineral content in the study of HIV-infected pregnant women and their infants. (13) Another safety concern of TDF is nephrotoxicity. TDF-related renal function impairment has been observed in patients with HIV infection (33) and with HBV infection. (11) The main target of nephrotoxicity appears to be the proximal renal tubule, leading to defective proximal tubular secretion (e.g. of creatinine) and reabsorption of several substances including phosphate. (11) Previous studies reported changes in renal function after TDF treatment for a median duration ranged from 6 to 45 months. (11, 33) For prevention of mother-to-infant transmission of HBV, TDF is used during late pregnancy, usually less than 2 to 3 months. Our previous study of TDF use to prevent maternal HBV transmission reported no difference in maternal serum creatinine levels at delivery, 1 month, and 6 months postpartum and no difference in infants' serum creatinine levels at 6 months of age. (15) The present study demonstrated that prenatal exposure of TDF does not affect these children's long-term renal function.
In this study, the duration of exposure to TDF is relatively short (8-12 weeks). All the mothers received short-term antiviral treatment from the 3rd trimester of pregnancy to 1 month postpartum. For women with indications for antiviral therapy before pregnancy or during pregnancy because of mother's own HBV disease activity, the continuing use of antiviral therapy, especially TDF throughout the whole pregnancy period is suggested by leading professional organizations (8, 9, 34) . Latest safety data from the antiretroviral pregnancy registry show that 4334 women had used TDF since the first trimester and there is no increased rates of birth anomaly (35) . With regard to women infected with HBV, because of small numbers of mothers receiving antiviral therapy since the first trimester, the real-world data or studies reporting the course and outcome of these mother-children pairs are lacking. Further investigations are needed.
There are limitations to this study. First, this is a non-randomized study. For a research starting in 2011 when safety data on antiviral nucleos(t)ide analogues therapy in HBV-infected pregnant women were insufficient, it was practically not feasible to conduct a double-blinded, randomized trial in pregnant women. We have minimized 16 the bias to the least extent by recruiting subjects with comparable baseline characteristics in both groups. (15) Second, not all subjects enrolled in the maternal TDF trial agreed to participate this follow-up study. Lastly, we did not perform early DXA measurement before 1 year of age. Nevertheless, we consider the data of bone development and metabolism markers above 2 years in this study are better representative of children's long-term growth and health.
In conclusion, TDF use during pregnancy to prevent mother-to-infant transmission of HBV is effective and safe. We demonstrated that children with and without TDF exposure during late pregnancy had comparable long-term growth, renal function and bone development, assessed by serum bone metabolism markers and DXA scans, up to 6-7 years of age. Our data provide important information for clinicians, highly viremic HBV-infected pregnant women and their families. The results confirm long-term safety in children with fetal TDF exposure, support TDF use among pregnant HBV-infected women, and contribute to global elimination of HBV infection. Tables   Table 1. Number of children and visits by Height Z score 0.18 ± 0.95 0.21 ± 1.08 0.966 * The children with history of breast milk ingestion consists of children fed breast milk exclusively and children fed mixed breast milk and formula during the first 6 months. Short-term TDF use during pregnancy to prevent maternal HBV transmission is safe.
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Figure Legends
Children with and without fetal exposure to TDF have comparable long-term growth.
Children's renal function and bone development are unaffected.
